Published in:
01-12-2009 | Short communication
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
Authors:
Eleanor Gutteridge, John FR Robertson
Published in:
Breast Cancer Research
|
Special Issue 3/2009
Login to get access
Excerpt
The process of drug development is expensive and time consuming, with millions of dollars spent on the testing of new chemical entities [
1,
2]. Unfortunately many agents that show initial promising activity against a particular biological target will be discarded due to concerns regarding their safety, toxicity and efficacy in humans. There is also a perception that preclinical models may foster unrealistic expectations, and many promising drugs are failing to reach their potential. In addition, reporting of clinical trials may disadvantage certain drugs at an early stage in their development. …